Evaluation of [18F]MC225-PET to Measure P-glycoprotein Function in Neurodegenerative Disease

Trial ID: NCT05853471

Interventional - Phase 1/2 - Unknown status

P-glycoprotein, an efflux transporter at the blood-brain barrier plays an important role in de development of neurodegenerative disease. A novel PET tracer (\[18F\]MC225) was developed to measure the function of P-glycoprotein and was tested with succes in healthy volunteers. This study aims to evaluate \[18F\]MC225 in neurodegenerative disease.

Conditions

• Neurodegenerative Diseases
• Alzheimer Disease
• Parkinson Disease
• Mild Cognitive Impairment

Interventions

• [18F]MC225

Eligibility

Inclusion criteria

• # Inclusion Criteria:
• * Patient is diagnosed with Alzheimer's disease, Parkinson's disease or Mild Cognitive Impairment

Exclusion criteria

• # Exclusion Criteria:
• * Use of any medication influencing the P-glycoprotein function
• * History of neuropsychiatric disorders
• * Contra-indications MRI
• * Allergy contrast agent

Sponsor

University Medical Center Groningen

Last updated: 2025-04-23 · Source: Clinicaltrials.gov

Search more clinical trials on myTomorrows